WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST Your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | By Ben Adams Pharma’s reputation may have soared amid the pandemic, but that came with a brighter spotlight on DEI issues. In recent years, pharma has been trying to penetrate social issues of diversity, equity and inclusion more deeply into its corporate psyche. read more |
| |
|---|
|
Top Stories Of The Week By Conor Hale Diabetes tracker developer Dexcom is pushing back the timeline for a U.S. launch of the latest generation of its continuous glucose monitor, the G7, after the FDA raised questions about the device’s software during a review. read more By Angus Liu Merck's Keytruda can cross another player off its potential competitor list in postsurgery kidney cancer. On the heels of a trial flop by Roche's Tecentriq, Bristol Myers Squibb's Opdivo-Yervoy combination has now also disappointed. read more By Max Bayer Another quarter, another cull for Moderna. The company snuck into its second-quarter earnings report that development of an mRNA treatment for IL-2-based autoimmune disorders has ended. read more By Eric Sagonowsky After years of government standstill on drug prices in the U.S., could the Senate this week pass a "watershed" bill enabling drug price negotiations? It remains to be seen, but analysts are busy poring over the available details to see how the legislation may affect the industry's top players. read more By Nick Paul Taylor AstraZeneca's first phase 3 bet on the anti-NKG2A antibody monalizumab has ended in failure. Adding the Innate Pharma-partnered molecule to Erbitux failed to improve outcomes in head and neck cancer patients at an interim analysis, prompting AstraZeneca to stop the study. read more By Zoey Becker With 132 patents for Humira, AbbVie has faced its share of critics alleging antitrust violations. Now, an appeals court ruled that AbbVie's Humira strategy holds up within the law. read more By Max Bayer Robert Califf threw his support behind the FDA's longstanding cancer czar, backing a proposal by Richard Pazdur for the agency to be more judicious in accepting single-arm trial data to nab accelerated approval. The prospect of limiting the trials has irked some in the biopharma industry. read more By Angus Liu Pfizer's Eucrisa never lived to become the next big topical treatment for inflammatory skin diseases. Now, young biotech Arcutis Biotherapeutics is bringing along a new therapy that goes after the same drug target but with a very different product profile. read more By Angus Liu The Allen Institute and its collaborators are drawing a comprehensive map of cellular and molecular changes during the development of Alzheimer’s, hoping to identify new targets for future therapies. And they have released the first findings. read more By Fraiser Kansteiner Both 20mg and 30mg tablets of Teva’s branded ADHD drug Adderall are currently on backorder in the U.S., with the company eyeing a release date in early- to mid-August, according to the American Society of Health-System Pharmacists (ASHP), which tracks current drug shortages. read more By Annalee Armstrong Layoffs are hitting biotech fast and furious. The Fierce Biotech Layoff Tracker is listing them all from Jan. 1 on. read more By Teresa Carey This week on "The Top Line," we explore why many early pandemic therapeutics are now throwing in the towel. We also chat about earnings season, and how biotechs' pipelines have changed, even the stuff that companies' are less keen to talk about. read more Resources Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
